Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 6/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4727501 | 0.85 | TK1 (0.41) | TK1LMNATSHRALBPKM | |
| SCHEMBL14388593 | 0.85 | TK1 (0.43) | TK1LMNATSHRALBPKM | |
| SCHEMBL27436150 | 0.85 | TK1 (0.43) | TK1LMNATSHRALBPKM | |
| SCHEMBL887851 | 0.84 | TK1 (0.43) | TK1LMNATSHRALBPKM | |
| SCHEMBL1517629 | 0.84 | TK1 (0.44) | TK1LMNATSHRALBPKM | |
| SCHEMBL29597386 | 0.84 | TK1 (0.39) | TK1 | |
| SCHEMBL5163085 | 0.84 | TK2 (0.43) | TK1 | |
| SCHEMBL28249854 | 0.83 | TK1 (0.42) | TK1LMNATSHRALBPKM | |
| SCHEMBL29587983 | 0.83 | TK2 (0.44) | TK1 | |
| SCHEMBL4728681 | 0.83 | TK1 (0.39) | TK1LMNATSHRALBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6743902-B1 | FOR USE IN ANTISENSE THERAPY FOR ENHANCING NUCLEASE RESISTANCE AND CELLULAR UPTAKE | VALEANT PHARMACEUTICALS INTERNATIONAL | 2004-06-01 | — | — | US | disclosed |
| US-6191266-B1 | MODIFIED TO COMPRISE SUBSTITUTIONS AT POSITIONS C1', C3', C4' OR C5' OF THE SUGAR MOIETY OF THE NUCLEOSIDE, INCLUDING AN OPTIONAL 3' PHOSPHOROAMIDITE GROUP; USE IN MAKING NUCLEASE RESISTANT OLIGONUCLEOTIDES FOR ANTISENSE THERAPY | ICN PHARMACEUTICALS, INC. | 2001-02-20 | — | — | US | disclosed |
| US-5712378-A | SUGAR MOLECULE IS SUBSTITUTED WITH HYDROCARBON OR SUBSTITUTED HYDROCARBON GROUPS, ANTISENSE AGENTS | ICN PHARMACEUTICALS (US) | 1998-01-27 | — | — | US | disclosed |
| US-5681940-A | CONTAIN TETRAHYDROTHIOPHENE OR PYROLIDINE RINGS | ICN PHARMACEUTICALS (US) | 1997-10-28 | — | — | US | disclosed |